Cytek Biosciences, Inc.
CTKB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001831915
No open-market purchases or sales by Cytek Biosciences, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $361.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Cytek Biosciences, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 52 | 74 | +22 |
| Shares | 35.0M | 47.7M | +12.7M (+36.2%) |
| Value | $571.9M | $514.5M | −$57.4M (−10.0%) |
New holders (29)
Institutions that held Cytek Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (7)
Institutions that held Cytek Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| OrbiMed Advisors LLC | 1,923,139 | $31.4M |
| Octagon Capital Advisors LP | 400,000 | $6.53M |
| Ergoteles LLC | 177,001 | $2.89M |
| Norges Bank | 33,443 | $546.0K |
| Cornerstone Investment Partners, LLC | 11,500 | $188.0K |
| Marshall Wace, LLP | 7,160 | $117.0K |
| STRS Ohio | 3,700 | $60.0K |